513 related articles for article (PubMed ID: 21168824)
1. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy.
Senturk F; Karacorlu M; Ozdemir H; Karacorlu SA; Uysal O
Am J Ophthalmol; 2011 Feb; 151(2):303-9.e1. PubMed ID: 21168824
[TBL] [Abstract][Full Text] [Related]
2. Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results.
Fujita K; Yuzawa M; Mori R
Retina; 2011 Apr; 31(4):772-8. PubMed ID: 20890236
[TBL] [Abstract][Full Text] [Related]
3. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M
Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
[TBL] [Abstract][Full Text] [Related]
4. Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Reibaldi M; Boscia F; Avitabile T; Uva MG; Russo A; Zagari M; Occhipinti F; Russo V; Reibaldi A; Longo A
Am J Ophthalmol; 2011 Jun; 151(6):953-960.e2. PubMed ID: 21457929
[TBL] [Abstract][Full Text] [Related]
5. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
[TBL] [Abstract][Full Text] [Related]
6. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
[TBL] [Abstract][Full Text] [Related]
7. Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
Gulkas S; Sahin O
Eur J Ophthalmol; 2020 Sep; 30(5):1053-1060. PubMed ID: 31256613
[TBL] [Abstract][Full Text] [Related]
8. Correlation of integrity of cone outer segment tips line with retinal sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
Fujita K; Shinoda K; Imamura Y; Matsumoto CS; Mizutani Y; Mizota A; Yuzawa M
Am J Ophthalmol; 2012 Sep; 154(3):579-85. PubMed ID: 22818904
[TBL] [Abstract][Full Text] [Related]
9. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.
Nicolò M; Zoli D; Musolino M; Traverso CE
Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224
[TBL] [Abstract][Full Text] [Related]
10. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
Cheng CK; Chang CK; Peng CH
Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
[TBL] [Abstract][Full Text] [Related]
11. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.
Nicoló M; Eandi CM; Alovisi C; Grignolo FM; Traverso CE; Musetti D; Cardillo Piccolino F
Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046
[TBL] [Abstract][Full Text] [Related]
12. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
Sheptulin V; Purtskhvanidze K; Roider J
Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
[TBL] [Abstract][Full Text] [Related]
13. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
[TBL] [Abstract][Full Text] [Related]
14. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study.
Silva RM; Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Gregório T; Cachulo ML; Pires IA; Cunha-Vaz JG; Murta JN
Retina; 2013 Feb; 33(2):309-15. PubMed ID: 23095766
[TBL] [Abstract][Full Text] [Related]
15. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy.
Lim JI; Glassman AR; Aiello LP; Chakravarthy U; Flaxel CJ; Spaide RF;
Ophthalmology; 2014 May; 121(5):1073-8. PubMed ID: 24439758
[TBL] [Abstract][Full Text] [Related]
16. The effect of photodynamic therapy on macular sensitivity in eyes with acute central serous chorioretinopathy.
Hagen S; Ansari-Shahrezaei S; Smretschnig E; Glittenberg C; Krebs I; Graf A; Binder S
Graefes Arch Clin Exp Ophthalmol; 2013 Apr; 251(4):1081-9. PubMed ID: 22926253
[TBL] [Abstract][Full Text] [Related]
17. Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.
Vasconcelos H; Marques I; Santos AR; Melo P; Pires I; Figueira J; de Abreu JF; Cachulo ML; Silva R
Graefes Arch Clin Exp Ophthalmol; 2013 Jul; 251(7):1697-705. PubMed ID: 23389551
[TBL] [Abstract][Full Text] [Related]
18. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy.
Shinojima A; Kawamura A; Mori R; Fujita K; Yuzawa M
Retina; 2011 Oct; 31(9):1912-20. PubMed ID: 21952105
[TBL] [Abstract][Full Text] [Related]
19. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.
Chan WM; Lai TY; Lai RY; Liu DT; Lam DS
Ophthalmology; 2008 Oct; 115(10):1756-65. PubMed ID: 18538401
[TBL] [Abstract][Full Text] [Related]
20. Short-Term Retinal Sensitivity and Metamorphopsia Changes following Half-Fluence Photodynamic Therapy in Central Serous Chorioretinopathy.
Casalino G; Del Turco C; Corvi F; Rafaeli O; Bandello F; Querques G
Ophthalmic Res; 2016; 56(1):23-9. PubMed ID: 27003789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
